Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.61 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.61 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.57 |
| ▸ | CA2 known ✓ | P00918 | 10/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 10/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.54 |
| ▸ | CA9 | Q16790 | 7/20 | 0.54 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2417149 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL587915 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL8516453 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL30849519 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL1555112 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| Hydrochloric Acid SCHEMBL3231613 | 0.98 | TDP1 (0.69) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL181700 | 0.98 | TDP1 (0.68) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL964035 | 0.96 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL368074 | 0.96 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA | |
| SCHEMBL220281 | 0.96 | TDP1 (0.71) | TDP1MAOAMAOBMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731606-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2026-04-29 | — | — | EP | disclosed |
| WO-2025261607-A1 | PARTICLES, COMPOSITIONS AND METHODS | BioNTech SE (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025027089-A1 | IONIZABLE THIOLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| WO-2025026545-A1 | IONIZABLE THIOPLIPIDS AND USES THEREOF | BioNTech SE (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-119072463-A | Novel ionizable cationic lipids | 维硕公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-118119598-A | Medicine for treating human tumor by eRF3a targeting protein degradation mechanism | 苏州德亘生物医药有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-117801051-A | Medicine for treating human tumor by eRF3a targeting protein degradation mechanism | 苏州德亘生物医药有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| WO-2023215906-A1 | KRAS G12D PROTEOLYSIS TARGETING CHIMERAS | HANGZHOU JIJING PHARMACEUTICALTECHNOLOGY LIMITED (CN) | 2023-11-09 | — | — | WO | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2012-05-03 | — | — | US | disclosed |
| EP-2443136-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | Neobiotics AB (SE) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010147547-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | NEOBIOTICS AB (SE) | 2010-12-23 | — | — | WO | disclosed |
| WO-2004082585-A2 | WATER-SOLUBLE CONJUGATES OF PHENYTOIN | SIRUS PHARMACEUTICALS LTD (GB) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004014350-A2 | POLYMER CONJUGATES OF A LOCAL ANAESTHETIC DRUG | SIRUS PHARMACEUTICALS LTD (GB) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014973-A2 | BIODEGRADABLE POLYMER | SIRUS PHARMACEUTICALS LTD (GB) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014841-A1 | COMPOUNDS, PRO-DRUGS AND CONJUGATES DERIVED FROM MEXILETINE | SIRUS PHARMACEUTICALS LTD (GB) | 2004-02-19 | — | — | WO | disclosed |
| EP-0566919-B1 | 2,4-dioxoimidazoline derivatives | HOECHST AG (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-5397796-A | Inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces | CASSELLA AG (DE) | 1995-03-14 | — | — | US | disclosed |
| EP-0566919-A1 | 2,4-dioxoimidazoline derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MAOA 2771/4885MAOB 2743/4885GAA 1234/4885 |
| US-20120108515-A1 | NOVEL PEPTIDE DERIVATIVES FOR TREATMENT, PREVENTION OR ALLEVIATION OF A CONDITION ASSOCIATED WITH BONE LOSS OR LOW BONE DENSITY OR TO INHIBIT OSTEOCLAST DIFFERENTIATION AND STIMULATION | BMP2, SOST, BMP1 | MAOA 4484/4885MAOB 4397/4885GAA 2265/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MAOA 2771/4885MAOB 2743/4885GAA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.